# Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Canonical URL: https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-commencement-of-tender-offer-by-kuva-labs-inc
Ticker: LSTA
Company: Lisata Therapeutics
Source: Lisata Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.lisata.com
## Summary

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction

## Article Body
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction
## Recent Company News
- 2026-06-25 13:46 EST — [Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-commencement-of-tender-offer-by-kuva-labs-inc) — Source: Lisata Therapeutics
- 2026-06-25 13:46 EST — [Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-announces-encouraging-preliminary-results-from-the-pancreatic-cancer-cohort-of-the-cendifox-trial) — Source: Lisata Therapeutics
- 2026-06-25 13:46 EST — [Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-and-catalent-announce-global-antibody-drug-conjugate-adc-license-agreement) — Source: Lisata Therapeutics
- 2026-06-25 13:46 EST — [Lisata Therapeutics to Present at LD Micro Main Event XIX](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-to-present-at-ld-micro-main-event-xix) — Source: Lisata Therapeutics
- 2026-06-25 13:46 EST — [Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025](https://biopharmsignal.com/news/LSTA/lisata-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-business-update-on-thursday-november-6-2025) — Source: Lisata Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)